PA8567601A1 - Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos - Google Patents

Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos

Info

Publication number
PA8567601A1
PA8567601A1 PA20038567601A PA8567601A PA8567601A1 PA 8567601 A1 PA8567601 A1 PA 8567601A1 PA 20038567601 A PA20038567601 A PA 20038567601A PA 8567601 A PA8567601 A PA 8567601A PA 8567601 A1 PA8567601 A1 PA 8567601A1
Authority
PA
Panama
Prior art keywords
salt
monohidrate
formulations
procedures
receptor agonist
Prior art date
Application number
PA20038567601A
Other languages
English (en)
Spanish (es)
Inventor
Jennifer Anne Lafontaine
Joseph Francis Krzyzaniak
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8567601A1 publication Critical patent/PA8567601A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PA20038567601A 2002-02-27 2003-02-26 Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos PA8567601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36024802P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
PA8567601A1 true PA8567601A1 (es) 2003-12-10

Family

ID=27766205

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20038567601A PA8567601A1 (es) 2002-02-27 2003-02-26 Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos

Country Status (8)

Country Link
AR (1) AR038603A1 (fr)
AU (1) AU2003248355A1 (fr)
GT (1) GT200300044A (fr)
PA (1) PA8567601A1 (fr)
PE (1) PE20030900A1 (fr)
TW (1) TW200305414A (fr)
UY (1) UY27678A1 (fr)
WO (1) WO2003072571A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
BR0114836A (pt) * 2000-10-20 2003-07-01 Pfizer Prod Inc Agonistas de receptores beta-3 adrenérgicos e suas aplicações

Also Published As

Publication number Publication date
AU2003248355A1 (en) 2003-09-09
UY27678A1 (es) 2003-10-31
AR038603A1 (es) 2005-01-19
WO2003072571A1 (fr) 2003-09-04
PE20030900A1 (es) 2003-10-25
GT200300044A (es) 2003-09-22
TW200305414A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
CL2004000257A1 (es) Compuestos heterociclil-3-sulfonilaza-indol o -indazol; su composicion farmaceutica; su procedimiento de preparacion; y su uso en el tratamiento de trastornos por deficit atencional, abstinencia producto de la adiccion a drogas, alcohol o nicotina, e
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CR9514A (es) Antagonistas de npy, preparacion y usos
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
GT201000160A (es) Derivados de aminobenzamida como agentes útiles para el control de parásitos de animales
MX2009002054A (es) Metodos para inhibir angiogenesis y tratamiento contra enfermedades asociadas con angiogenesis.
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
GT200300075BA (es) Compuestos que modulan la actividad ppar y procedimientos para su preparacion (patente fraccionaria no. 2 de la solicitud no. pi-20030075)
DK1178736T3 (da) Præparat indeholdende carvacrol og thymol til anvendelse som et bakteriedræbende middel
GT200500378A (es) Macrolidos
CR7168A (es) Ligandos del receptor de 5.ht y sus usos
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
AR049876A1 (es) Composiciones farmaceuticas para tratar enfermedades de la piel que comprenden una combinacion de epinastina y uno o mas minerales adicionales o uno o mas farmacos brutos
BR112012015961A2 (pt) composições incluindo piruvato para animais de estimação e métodos de uso dos mesmos
CL2003002720A1 (es) Compuestos derivados de pirrol, sus sales, composicion farmaceutica, procedimiento de preparacion, utiles para tratar obesidad, desordenes psiquiatricos, parkinson, alzheimer, desordenes inmunes, cardio vasculares, reproductivos y endocrinos, entre o
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones
CL2012001671A1 (es) Compuestos derivados de (metilsulfonil)-etil-bencenoisoindolina; composicion farmaceutica que los comprende, uso en el tratamiento del cancer, dolor, trastornos del snc, enfermedades dermatologicas, entre otras.
PA8600001A1 (es) Compuestos de 4-fenil piperidina y sus usos como modulador del receptores opioides
CL2004000102A1 (es) Compuestos derivados de amidas sustituidas por carbociclos, composicion farmaceutica, utiles para tratar obesidad, hipercolesterolemia, depresion, enfermedades de la piel, cancer de tiroides y otras.
PT979224E (pt) Composicoes solidas adequadas para administracao oral compostas por l-carnitina ou alcanoil-l-carnitina fuarato de magnesio
PA8567601A1 (es) Sal agonista del receptor b3-adrenergico, sus formulaciones y sus usos
PA8567501A1 (es) Formas cristalinas de agonistas del receptor b3-adrenergico, procedimientos para su preparacion, y sus usos
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
MY159348A (en) A novel stable formulation for treatment of respiratory disorder